Not yet recruiting
Prostate cancer
Not yet recruitingPhase 1 Study of Terbium (161TB) Zadavotide Guraxetan as Neoadjuvant Treatment in Very High‑Risk Prostate Cancer Patients Eligible for Surgery
InvestigationalNo placebo
Phase 1 Study of Terbium (161TB) Zadavotide Guraxetan as Neoadjuvant Treatment in Very High‑Risk Prostate Cancer Patients Eligible for Surgery
InvestigationalNo placebo
- Disease:Prostate cancer
- Substances:Terbium (161TB) zadavotide guraxetan
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Terbium (161TB) zadavotide guraxetan
